Rigel Pharmaceuticals, Incorporated

Epiodyne, Inc.

Bristol-myers Squibb Compnay

Tenaya Therapeutics, Inc.

Pingyu Ding

Rajinder Paul Singh

Sacha Holland

Jiaxin Yu

Dane A Goff

Thilo J Heckrodt

Jing Zhang

Somasekhar Bhamidipati

Joane Litvak

Vanessa Taylor

Hui Li

Yan Chen

Rose Yen

Jeffrey Clough

Esteban Masuda

Darren J McMurtrie

Ankush Argade

Ihab S Darwish

Todd M Kinsella

Marina Gelman

Dane Goff

Donald G Payan

Julio Cesar Medina

Rao Kolluri

Ulhas Bhatt

Alok Nerurkar

Frederick Seidl

Thomas T Nguyen

Sambaiah Thota

Hui Hong

Xiaodong Wang

Jason A Duquette

Andy Atuegbu

Zhi-Liang Wei

Yihong Li

Tien Widjaja

Catherine Sylvain

David Sperandio

Corinne Sadlowski

Vadim Markovtosov

Martin Holan

John Lee

Heng Cheng

Robert Michael Borzilleri

Lawrence R McGee

Snahel Patel

Upender Velaparthi

Jayakumar Sankara Warrier

Hasibur Rahaman

Vadim Markovtsov

Mohammad A Mandegar

Sambiah Thota

Darren John Mcmurtrie

Larry Mcgee

Sambaiah Thhota

Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.

Fluoroalkyl-oxadiazoles and uses thereof

Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Opioid receptor modulators

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Tyrosine kinase inhibitors

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R, R, R, R, R, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.

Opioid receptor modulators and products and methods related thereto

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

Compositions and methods for inhibition of the JAK pathway

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure  and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R' are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-&#x3b2; superfamily, and can be used to treat disease by blocking such activity. 

TGF-&#xdf; inhibitors

The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-&#x3b2; superfamily such as Nodal or Activin.

2,3-Disubstituted pyridine compounds as TGF-&#x3b2; inhibitors and methods of use

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-&#x3b2; superfamily such as Nodal or Activin. 

2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Substituted triazoles useful as Axl inhibitors

Growing community of inventors

Foster City, CA, United States of America

Pingyu Ding